A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities

Abstract only

Saved in:

Bibliographic Details
Published in	Journal of clinical oncology Vol. 29; no. 15_suppl; p. 6537
Main Authors	Butera, J., Winer, E., Wang, C., Castillo, J. J., Thomas, A. G., Safran, H., Mega, A. E., Colvin, G. A., Rathore, B., Quesenberry, P. J.
Format	Journal Article
Language	English
Published	20.05.2011
Online Access	Get full text

Loading…